dolcanatide

Peptideexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 27, 2018 (NCT03300570)

Timeline

2010s

Jan 1, 2018
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Colorectal Neoplasms · Phase 1

Mechanism of action

Guanylate cyclase activator 2BAGONIST
GUCA2B agonist
- Guanylate cyclase activator 2B (GUCA2B) ↗
Heat-stable enterotoxin receptorAGONIST
Heat-stable enterotoxin receptor agonist
- Heat-stable enterotoxin receptor (GUCY2C) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](CC(C)C)C(=O)O)CSSC[C@@H](C(=O)N[C@H](C(=O)O)C(C)C)NC1=O

Mol. weight: 1699.93 g/mol
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL3545122 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03300570	Phase 1	Jul 27, 2018	Mayo Clinic, National Cancer Institute (NCI)

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Mayo Clinic	Academic/Hospital	1	0	1	2018
National Cancer Institute (NCI)	Government	1	1	1	2018

2 organizations

Page 1 / 1